Current Price
Target Price
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of cancer therapies for cancers with critical unmet medical needs. The company is headquartered in San Diego, Californi...|
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
| Metric (B) | FY 2023 | FY 2023 | FY 2023 | FY 2023 | FY 2024 | FY 2024 | FY 2024 | FY 2024 | FY 2025 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| $-0.20 | $-0.16 | $-0.14 | $-3.07 | $-2.88 | $-3.10 | $-3.19 | $-3.47 | $-2.29 | $-10.25 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| +9.1% | +0.0% | +0.0% | +0.0% | -0.3% | +0.0% | +0.0% | -17.2% | +0.0% | -11.6% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | RRevelation... | REVB | $2.43M | — | 0.34 | — | — | -133.40% | — |
| 2. | CClearmind... | CMND | $2.30M | — | 0.18 | — | — | -107.00% | — |
| 3. | PPropanc Bi... | PPCB | $2.01M | — | 0.20 | — | — | -161.90% | — |
| 4. | PPurple Bio... | PPBT | $2.65M | — | 0.22 | — | — | -111.10% | — |
| 5. | GGenprex In... | GNPX | $1.71M | — | 0.12 | — | — | -203.90% | — |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Mar 24 | Jun 24 | Sep 24 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0.17 | 0.17 | 0.11 | 0.18 | 0.3 | 0.57 | 0.8 | 0 |
COGS | 0.04 | 0.04 | 0.04 | 0.07 | 6.67 | 6.06 | 5.9 | 0 |
Gross Profit | 0.14 | 0.14 | 0.07 | 0.1 | -6.37 | -5.49 | -5.1 | 0 |
Gross Profit % | 79.53% | 79.53% | 65.09% | 58.1% | -2145.79% | -964.85% | -636.7% | - |
| 11.91 | 12.14 | 9.54 | 10.39 | 9.93 | 9.35 | 9.66 | 8.68 | |
EBIT | -11.91 | -12.14 | -9.54 | -10.39 | -9.64 | -8.78 | -8.86 | -8.68 |
OPM % | -6967.84% | -7101.17% | -9004.72% | -5804.47% | -3244.44% | -1542.88% | -1106.49% | - |
Non-Operating Income | 0.52 | 0.66 | 0.58 | 0.53 | 0.47 | 0.39 | 0.3 | 0.22 |
PBT | -11.4 | -11.49 | -8.97 | -9.86 | -9.16 | -8.39 | -8.56 | -8.46 |
Income Tax | -0.52 | -0.52 | -0.04 | -0.07 | -9.64 | -8.78 | -8.86 | 0 |
Tax Rate % | 4.52% | 4.48% | 0.41% | 0.76% | 105.15% | 104.66% | 103.55% | - |
Net Income | -10.88 | -11.49 | -8.97 | -9.86 | -9.16 | -8.39 | -8.56 | -8.46 |
NPM % | -6365.5% | -6717.54% | -8458.49% | -5509.5% | -3085.52% | -1474.17% | -1068.54% | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | -2.51 | 1.67 | 2.52 | 2.42 | 3.38 | 4.32 | 1.49 | 0.79 |
COGS | 0 | 0.04 | 2.51 | 9.36 | 0.05 | 10.16 | 12 | 0.17 | 0.18 | 29.75 |
Gross Profit | 0 | -0.04 | -5.02 | -7.69 | 2.48 | -7.73 | 3.38 | 4.32 | 1.49 | -28.97 |
Gross Profit % | - | - | 200% | -459.32% | 98.18% | -318.93% | 100% | 100% | 100% | -3690.19% |
| 30.35 | 21.84 | 25.93 | 30.66 | 39.06 | 15.02 | 17.54 | 31.37 | 44.95 | 12.75 | |
EBIT | -30.35 | -21.84 | -25.93 | -30.66 | -39.06 | -33.11 | -17.54 | -31.37 | -44.95 | -41.71 |
OPM % | - | - | 1032.78% | -1831.24% | -1549.35% | -1365.28% | -519.76% | -726.91% | -3016.58% | -5313.89% |
Non-Operating Income | 0 | 0 | 8.21 | 0.22 | 0.64 | -1.08 | 0.32 | 0.03 | 0.78 | 2.23 |
PBT | -39.41 | -18.7 | -17.72 | -30.44 | -38.42 | -34.19 | -17.23 | -31.33 | -44.17 | -39.48 |
Income Tax | 8.7 | -3.12 | -8.19 | -0.05 | 0.64 | -18.28 | -0.02 | -0.03 | -0.78 | -41.71 |
Tax Rate % | -22.08% | 16.7% | 46.21% | 0.15% | -1.67% | 53.46% | 0.09% | 0.11% | 1.76% | 105.66% |
Net Income | -39.41 | -18.7 | -17.72 | -30.44 | -38.42 | -15.91 | -17.21 | -31.3 | -43.39 | -39.48 |
NPM % | - | - | 705.85% | -1818.34% | -1523.92% | -656.16% | -509.9% | -725.38% | -2912.28% | -5029.17% |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| 17.88 | 14.06 | 8.91 | 15.82 | 28.26 | 20.05 | 116.74 | 90.77 | 37.14 | 6.7 | |
| 31.41 | 15.2 | 12.96 | 28.08 | 0.2 | 0 | 0 | 0 | 26.58 | 27.56 | |
| 0.03 | 0.01 | 0.08 | 0.05 | 0.02 | 0.19 | 0.04 | 0.07 | 0.09 | 0 | |
| 1.71 | 5.27 | 4.86 | 2.79 | 2.75 | 1.47 | 2.53 | 1.5 | 3.67 | 1.8 | |
| -0.39 | -2.5 | -2.31 | -0.51 | 0.09 | 0.03 | -0.5 | 1.24 | 1.17 | 0.67 | |
Total Assets | 50.65 | 32.03 | 24.5 | 46.24 | 31.32 | 21.74 | 118.81 | 93.58 | 68.65 | 36.73 |
| 0.14 | 0.14 | 0.02 | 0.02 | 0.02 | 0.01 | 0.05 | 0.05 | 0.06 | 0 | |
| 17.69 | 1.72 | 19.88 | 38.24 | 26.09 | 14.3 | -82.85 | -114.18 | -158.36 | 30.05 | |
| 0 | 0 | 0 | 0.2 | 46.59 | 0.19 | 0.04 | 0.07 | 0.09 | 0.32 | |
| 32.79 | 30.17 | 4.61 | 7.97 | 5.21 | 3.5 | 4.18 | 5.39 | 7.59 | 5.03 | |
| 0.03 | 0 | 0 | -0.2 | -46.59 | 3.74 | 1.63 | 0 | 0 | 1.33 | |
Total Liabilities | 50.65 | 32.03 | 24.5 | 46.24 | 31.32 | 21.74 | -76.94 | -108.67 | -150.62 | 36.73 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| -28.76 | -20.04 | -20.78 | -23.46 | -39.35 | -16.75 | -17.5 | -26.59 | -36.7 | -32.16 | |
| -31.22 | 16.21 | 2.15 | 16.14 | 16.14 | 16.14 | -26.5 | -26.5 | -26.5 | 0 | |
| 63.33 | 0 | 13.48 | 45.49 | 23.91 | 0.01 | 114.18 | 0.62 | 9.58 | 1.07 | |
Net CFNet Cash Flow | 3.35 | -3.82 | -5.15 | 6.91 | 12.44 | -0.59 | 96.69 | -52.47 | -53.62 | -31.1 |
FCFFree Cash Flow | -28.76 | -20.04 | -20.87 | -23.46 | -39.35 | -16.75 | -17.5 | -26.59 | -36.7 | -32.16 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| -276.4% | -190.0% | -163.0% | -104.7% | -119.4% | -78.7% | 50.3% | 31.8% | 31.9% | 61.6% | |
| - | - | - | 0.01 | 1.78 | 0.01 | -0.00 | -0.00 | -0.00 | 0.01 | |
| 1.53 | 1.06 | 5.27 | 5.78 | 5.99 | 2.83 | 20.14 | 16.99 | 8.76 | 6.94 | |
| - | - | -0.09 | 0.05 | 0.07 | 0.09 | 0.05 | 0.04 | 0.02 | 0.01 | |
Cash Conversion | 0.73 | 1.07 | 1.17 | 0.77 | 1.02 | 1.05 | 1.02 | 0.85 | 0.85 | 0.81 |
Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| - | - | - | 166.7% | 50.6% | -3.8% | 39.2% | 27.9% | -65.5% | -47.3% | |
| - | - | - | - | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | - | - | - | |
| 3.00 | 2.00 | 3.00 | 5.00 | 4.00 | 4.00 | 4.00 | 4.00 | 2.00 | 3.00 | |
| - | - | - | - | -4.86 | 1.73 | -4.31 | -2.66 | -4.12 | 1.30 | |
| 0.00 | 0.00 | 0.00 | 33.33 | 33.33 | 33.33 | 100.00 | 100.00 | 100.00 | 33.33 | |
| - | - | 7.1% | -18.2% | -15.2% | -6.6% | -5.1% | -7.3% | -29.1% | -50.3% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns Oncternal Therapeutics Inc, from SEC filings
Who owns the company, quarter by quarter
Calendar quarters (13F report dates). Mar 2026 can still change as late 13F amendments arrive.
| Shares held | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | QoQ |
|---|---|---|---|---|---|---|---|---|---|
| 1.2M | 1.2M | 1.2M | 1.2M | 1.1M | 1.1M | 1.1M | 10.0K | -1.1M | |
ForeignForeign institutions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
USUS institutions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Govt.Government & pensions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of institutional holders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insiders = officers, directors and 10% owners (Forms 3/4/5). Foreign vs US = the 13F manager's registered address. Government = sovereign funds, central banks and public pensions. Public includes retail investors and funds below the $100M 13F threshold. Named holders are the largest 13F filers each quarter; shares outstanding come from the 10-K / 10-Q cover page.
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 29 Nov 2024 | 138,615 | +875.5% | 1.00 | |
| 15 Nov 2024 | 14,209 | -68.7% | 1.00 | |
| 31 Oct 2024 | 45,352 | +167.8% | 1.00 | |
| 15 Oct 2024 | 16,932 | -5.3% | 1.00 | |
| 30 Sep 2024 | 17,887 | -26.1% | 1.00 | |
| 13 Sep 2024 | 24,205 | +78.8% | 1.00 | |
| 30 Aug 2024 | 13,541 | -12.0% | 1.00 | |
| 15 Aug 2024 | 15,389 | -12.2% | 1.59 | |
| 31 Jul 2024 | 17,519 | -17.9% | 3.28 | |
| 15 Jul 2024 | 21,330 | +4.4% | 2.61 | |
| 28 Jun 2024 | 20,424 | +1.3% | 3.44 | |
| 14 Jun 2024 | 20,152 | -3.5% | 3.26 | |
| 31 May 2024 | 20,876 | -9.6% | 3.29 | |
| 15 May 2024 | 23,088 | +78.3% | 4.85 | |
| 30 Apr 2024 | 12,951 | -6.1% | 4.55 | |
| 15 Apr 2024 | 13,798 | -17.6% | 1.51 | |
| 28 Mar 2024 | 16,735 | +11.6% | 2.56 | |
| 15 Mar 2024 | 15,001 | -6.5% | 1.20 | |
| 29 Feb 2024 | 16,037 | -28.0% | 2.33 | |
| 15 Feb 2024 | 22,273 | -10.7% | 2.40 | |
| 31 Jan 2024 | 24,952 | +24.7% | 1.41 | |
| 12 Jan 2024 | 20,002 | -92.4% | 1.00 | |
| 29 Dec 2023 | 262,385 | +8.7% | 1.00 | |
| 15 Dec 2023 | 241,377 | -22.1% | 1.00 |
FINRA consolidated short interest, reported twice a month for every US listing.
Oncternal Therapeutics Inc's SEC filings and earnings call transcripts
What recent news says about Oncternal Therapeutics Inc, scored for sentiment.